arrow
K

Kyu-pyo Kim

Asan Medical Center
H指数:40
被引数:5,734

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world outcomes of lenvatinib versus sorafenib as the second-line therapy after atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: a large-scale multicenter study in Korea

仑伐替尼与索拉非尼作为阿替利珠单抗联合贝伐珠单抗后肝癌患者的二线治疗真实世界疗效:一项韩国大规模多中心研究

2026-09-110
OAAI
Molecular profiling of pancreatic acinar cell carcinoma and amphicrine-like carcinoma: high frequency of homologous recombination deficiency and molecular heterogeneity

胰腺腺泡细胞癌和类混合分泌型癌的分子特征分析:同源重组缺陷高发及分子异质性

2026-09-050
PRE
Real-World Comparison of Lenvatinib and Sorafenib as First-Line Treatments for Hepatocellular Carcinoma: A Multicenter Study

Lenvatinib和Sorafenib作为肝细胞癌一线治疗的真实世界比较:一项多中心研究

2025-11-250
OAAI
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials

脂质体伊立替康用于先前接受过治疗的患者胆道癌:NIFTY和NALIRICC试验的合并分析

2025-03-250
OAAI
Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials

二线以氟嘧啶为基础的化疗在晚期胆道癌中的应用:一项基于随机试验个体患者数据的Meta分析

2024-10-170
OA